Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13240)	12/19/2003 1:19:00 PM
From: Joe Krupa	Respond to of 14101

Further to my last two posts, I think this paragraph sums up the obstacles, inefficiencies and potential politics that face any drug under review for formulary listing. "Part of how provinces are attempting to cope with rising costs is through the newly created Common Drug Review, in which a committee reviews newly approved drugs for their cost-effectiveness before recommending whether they should be put onto provincial formularies. If a drug is found to be ‘costeffective’ -- the definition for which has not been made public, it is important to note -- provincial formulary program functionaries will then re-review it for the purpose of determining whether or not to place it on their formularies. If a drug is found by CDR to be not ‘cost-effective’, provinces will simply not even consider it. There are many issues regarding CDR that need to be addressed, including the lack of transparency regarding review criteria, the lack of consumer participation on the review committee, the duplication of reviews by provinces, and the very mandate of CDR, which is to contain costs rather than to ensure that consumers have the most timely access to safe and effective medicines." bcpwa.org joe